Can a daily capsule of nicotinamide riboside and pterostilbene raise NAD+ in older adults? In the first-in-human NRPT (Basis) trial, 120 people aged 60 to 80 took it for eight weeks. Blood NAD+ rose about 40% at the recommended dose and about 90% at double the dose, and the rise held steady through the study. No serious adverse events were reported. Here is what the numbers show, what the dose takeaways are, and what the study cannot tell you.
This page is available in